+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SUVEN

Suven Life Sciences Share Price

₹317.80 -8.75 (-2.68%)
156.06% Gain from 52W Low

06 Aug, 2026 3:51 PM (IST)

Suven Life Sciences live price: ₹317.80. It opened at ₹325 vs previous close ₹327; intraday high/low: ₹325/₹307. The 50 & 200 DMA stand at ₹294.20/₹229.20.

Suven Life Sciences Performance

  • Today's Low
  • ₹307
  • Today's High
  • ₹325
  • 52 Week Low
  • ₹124
  • 52 Week High
  • ₹371
  • Open Price₹325
  • Previous Close₹327
  • Volume859,917
  • 50 DMA₹294.20
  • 100 DMA₹261.10
  • 200 DMA₹229.20

Suven Life Sciences Chart

Investment Returns

  • Over 1 Month -2.99%
  • Over 3 Month + 54.31%
  • Over 6 Month + 92.45%
  • Over 1 Year + 18.56%

Smart Investing Starts Here Start SIP with Suven Life Sciences for Steady Growth!

Invest Now

Suven Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -25.5
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 8,980
  • P/B Ratio
  • 15.1
  • Average True Range
  • 18.2
  • EPS
  • -12.5
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.6
  • RSI
  • 52.62
  • MFI
  • 49.86

Latest Stock News Updates

Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Adv. regarding Notice of 37th Annual General Meeting of the Company and E-voting information

Suven Life Sciences Ltd - 530239 - Board Meeting Intimation for Consideration Of Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June, 2026

Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results of the Company (Standalone and Consolidated) for the quarter ended 30th June, 2026 and related matters

Suven Life Sciences Ltd - 530239 - Letter To Shareholders Regarding Annual Report FY 2025-26

Letter to Shareholders regarding Annual Report FY 2025-26

Suven Life Sciences Financials

Suven Life Sciences Technicals

EMA & SMA

Current Price
₹317.80
-8.75 (-2.68%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹314.50
  • 50 Day
  • ₹294.20
  • 100 Day
  • ₹261.10
  • 200 Day
  • ₹229.20

Resistance and Support

316.67 Pivot Speed
  • R3 343.90
  • R2 334.40
  • R1 326.10
  • S1 308.30
  • S2 298.80
  • S3 290.50

Suven Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-06 Quarterly Results
2026-05-13 Audited Results
2026-01-29 Quarterly Results
2025-11-11 Quarterly Results
2025-08-13 Quarterly Results
Date Purpose Remarks
2007-04-02 Split Stock split from Rs. 2/- to Re. 1/- & Bonus @ 1:1.
2004-01-23 Split Subdivision of Equity Shares into face value of Rs 2/- each

Suven Life Sciences Shareholding Pattern

70.08%
26.42%
2.92%
0.56%
0.01%

About Suven Life Sciences

Suven Life Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function. View More
  • NSE Symbol
  • SUVEN
  • BSE Symbol
  • 530239
  • ISIN
  • INE495B01038

Similar Stocks to Suven Life Sciences

Suven Life Sciences FAQs

Suven Life Sciences share price is ₹317 As on 07 August, 2026 | 00:03

The Market Cap of Suven Life Sciences is ₹8979.8 Cr As on 07 August, 2026 | 00:03

The P/E ratio of Suven Life Sciences is -25.5 As on 07 August, 2026 | 00:03

The PB ratio of Suven Life Sciences is 15.1 As on 07 August, 2026 | 00:03

The 52 week High & Low of Suven Life Sciences is ₹371/₹124.1 respectively As on 07 August, 2026 | 00:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23